[Market Focus] L&C Bio Accelerates Global Expansion of Skin Boosters with Two-Shift Operations and Facility Expansion

Shares of L&C Bio, a regenerative medicine specialist, are showing strong performance. The news that the company is set to actively target the Japanese beauty and medical market following Singapore appears to be influencing its stock price. L&C Bio has begun operating its production lines in two shifts and expanding additional facilities to respond to increasing domestic and international demand.

As of 9:10 a.m. on September 24, L&C Bio was trading at 61,100 won, up 3,600 won (6.26%) from the previous trading day.

On this day, L&C Bio announced that it had signed a strategic partnership with distributor PRSS JAPAN and would supply its ECM (extracellular matrix)-based skin booster, Ellavi? Lituo (branded as BNAJU in Japan), to Japan’s largest beauty and medical network.

Through this agreement, PRSS JAPAN will serve as the official distribution partner and will begin supplying BNAJU to beauty and medical network branches starting next month. BNAJU stands for "Beauty and Natural Rejuvenation," reflecting the brand’s concept of natural skin recovery.

PRSS JAPAN is a specialized distributor that has supported the entry of global beauty and medical products into the Japanese market. Leveraging its experience with Japan’s medical institution networks and regulatory compliance, the company has a strong advantage in helping new products establish themselves in the market. The plan is to supply products to approximately 150 locations nationwide through Japan’s leading beauty clinic network, which attracts millions of visitors annually.

An L&C Bio representative stated, "We are not stopping at expanding our global supply chain to Japan following Singapore, but also actively planning to enter other major Asian markets in the future. To respond to increasing domestic and international demand, we are operating our production lines in two shifts and expanding additional facilities."

Lee Seungeun, a researcher at Yuanta Securities, introduced Ellavi? Lituo as a product that utilizes human dermis-derived ECM to directly replenish collagen, elastin, and hyaluronic acid, providing immediate improvement after procedures and a long-lasting effect.

He added, "Currently, it is being produced in the Megafil section of the first plant. As of the first half of this year, production capacity has doubled compared to the previous year, and the utilization rate has reached about 60%."

He further estimated, "Production capacity is estimated at around 10 billion won, and it can be expanded smoothly up to about 20 billion won."

L&C Bio’s expansion lead time is short, at just 2 to 6 months, allowing the company to respond quickly to increased demand. This helps mitigate supply bottleneck risks. The researcher analyzed, "More than 95% of raw materials are supplied by U.S. tissue banks, and the company holds AATB certification, ensuring global standards of stability and safety."

He also noted, "Currently, the company has secured more than two years’ worth of raw materials in advance, minimizing supply chain risks. Plans are also in place to convert to a dedicated Lituo line and further expand facilities, which will stably support sales growth in line with the pace of channel expansion."